A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.
